BackElevance Health Overview
Elevance Health Inc

Elevance Health Target Price

Analysts' average 12-month price target for Elevance Health is $460.

Get informed when a big investor buys or sells

+ Follow

Share Price

$429.69

Average Target Price

$458.406.7% upside

20 analysts in the last 4 months

High: $523 | Low: $393

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-10-23Mizuho SecuritiesAnn Hynes$49014% upsideOpen
2026-10-23Goldman Sachs$4515% upsideOpen
2026-10-23Piper Sandler$52021% upsideOpen
2026-10-22RBC Capital$4555.9% upsideOpen
2026-10-22UBS$52321.7% upsideOpen
2026-10-22GuggenheimJason Cassorla$48512.9% upsideOpen
2026-10-22Robert W. Baird$4065.5% downsideOpen
2026-10-22Barclays$4729.8% upsideOpen
2026-10-12GuggenheimJason Cassorla$4607.1% upsideOpen
2026-10-07Barclays$4699.1% upsideOpen
2026-07-17Leerink Partners$3958.1% downsideOpen
2026-07-16RBC Capital$4241.3% downsideOpen
2026-07-16New Street$48212.2% upsideOpen
2026-07-16Goldman Sachs$3958.1% downsideOpen
2026-07-16Bernstein$48813.6% upsideOpen
2026-07-16Robert W. Baird$3938.5% downsideOpen
2026-07-16Barclays$4576.4% upsideOpen
2026-07-16Wells FargoStephen Baxter$47310.1% upsideOpen
2026-07-16Guggenheim$4555.9% upsideOpen
2026-07-14Truist Financial$47510.5% upsideOpen
2026-07-13Wells Fargo$49214.5% upsideOpen
2026-07-09RBC CapitalBen Hendrix$4392.2% upsideOpen
2026-07-07Raymond JamesSarah James$4504.7% upsideOpen
2026-07-02Bernstein$48212.2% upsideOpen
2026-06-08Mizuho Securities$4658.2% upsideOpen
2026-06-04Morgan Stanley$4046% downsideOpen
2026-06-01Truist FinancialDavid MacDonald$4504.7% upsideOpen
2026-05-26BarclaysAndrew Mok$48011.7% upsideOpen
2026-05-22UBS$4607.1% upsideOpen
2026-05-20Deutsche Bank$49815.9% upsideOpen
2026-05-20Mizuho Securities$4351.2% upsideOpen
2026-04-24Guggenheim$3997.1% downsideOpen
2026-04-24Barclays$4085% downsideOpen
2026-04-23Leerink Partners$36415.3% downsideOpen
2026-04-23Robert W. Baird$33123% downsideOpen
2026-04-20JefferiesDavid Windley$3919% downsideOpen
2026-03-10Mizuho SecuritiesAnn Hynes$35018.5% downsideOpen
2026-02-03RBC Capital$35816.7% downsideOpen
2026-02-02Truist Financial$3909.2% downsideOpen
2026-02-02Piper Sandler$4094.8% downsideOpen
2026-02-02Craig-Hallum$4094.8% downsideOpen
2026-02-01Bernstein$4094.8% downsideOpen
2026-01-30Barclays$3938.5% downsideOpen
2026-01-30Wells Fargo$3919% downsideOpen
2026-01-29UBS$4006.9% downsideOpen
2026-01-29GuggenheimJason Cassorla$3967.8% downsideOpen
2026-01-29Deutsche Bank$33222.7% downsideOpen
2026-01-22GuggenheimJason Cassorla$4143.7% downsideOpen
2026-01-09Mizuho SecuritiesAnn Hynes$4133.9% downsideOpen
2026-01-08Wolfe ResearchJustin Lake$4251.1% downsideOpen

Elevance Health (ELV) FAQ

Elevance Health posts a target price of $460. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $460 for ELV means covering analysts, on average, see the stock 6.7% upside of $429.69 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for ELV's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Elevance Health's other metric pages and overview cover the third.

Judging Elevance Health against Finance peers is usually better than using a market-wide rule of thumb. Business models inside Finance are more comparable, which makes gaps in target price easier to interpret. Start with $460 here, then scan peer and history charts to see if the gap is persistent.